CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

This study is testing a new type of immune cell therapy called CD79b-19 CAR T cells for people with relapsed or hard-to-treat Non-Hodgkin Lymphoma (NHL). CAR T therapy takes your own immune cells, engineers them in a lab to attack cancer, and infuses them back into your body. This version targets two proteins (CD79b and CD19) found on certain lymphoma cells. **You may be eligible if...** - You are 18 or older with relapsed or treatment-resistant Non-Hodgkin Lymphoma (including follicular, marginal zone, diffuse large B-cell, mantle cell, or transformed lymphoma) - You have received at least 2 prior lines of treatment - Your heart, liver, and kidneys are functioning well enough - You are willing to use birth control during and after treatment **You may NOT be eligible if...** - You have active central nervous system lymphoma - You have severe heart failure or a recent heart attack - You are pregnant or breastfeeding - You received certain other cell therapies (like CAR T) very recently Talk to your doctor to see if this trial is right for you.